ClinicalTrials.gg
RecruitingNCT05824169Updated Nov 17, 2026

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

A Phase 1/2 interventional study of GC101 in Spinal Muscular Atrophy, sponsored by GeneCradle Inc. Recruiting at 4 sites in China. Open to participants aged 0 Months to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GeneCradle Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
0 Months to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.

Planned enrollment
13th of 16
18 · median 35
Started
2023
with 1 other
Phase 1/2
2 of 23
1 open now
Primary completion
2026-12
later than 1 of 12 live
Registered
14th of 23
by date
Lead sponsor
2 of 23
GeneCradle Inc

Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1/2, reaches primary completion later than 1 of the 12 other live ones, and was the 14th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 0 Months to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy, Spinal with a site in China, or all of them as a file.
02

Study summary

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.

Read the detailed description

The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 1 patients. Open-label, dose-escalation clinical trial of GC101 will be conducted in multiple centers in China.

GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up on various time points.

The primary analysis for efficacy will be assessed when all patients reach 18 months of age on the motor milestone of sit unassisted for at least 10 seconds.

03

Conditions studied

  • Spinal Muscular Atrophy

Keywords

  • Type 1
04

Who can participate

Ages eligible
0 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Six months of age and younger on day of vector infusion with Type 1 SAM as defined by the following features:

    • Diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations (deletion or point mutations) and 2 copies of SMN2;
    • Onset of disease before 6 months of age
  • The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated prior to any study-related procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Patient who has participated in a previous gene therapy research trials;
  • Patient who has received Nusinersen and Risdiplam treatment;
  • Patient who has AAV9 neutralizing antibody titer ≥1:200;
  • Patient who requires non-invasive ventilatory support averaging≥16 hours/day;
  • Patient with a point mutation in SMN2 (c.859G>C);
  • Patient who requires non-invasive ventilatory support averaging≥16 hours/day at screening;
  • Patient who use invasive ventilatory support or pulse oximetry \< 95% saturation while awake and calm at screening;
  • Patient who is positive for (HIV) antibody, surface antigen, antibody, or treponema pallidum antibody;
  • Abnormal laboratory values considered , including gamma-glutamyl transferase(GGT), (AST), alanine aminotransferase (ALT), > 3x (ULN), (Hgb)\< 110 or >150 g/L, \<183x10\^9/L or 614x10\^9/L;
  • Class IV patient based on Modified Ross Heart Failure Classification for Children;
  • Patient with a history of allergy;
  • that would interfere with the lumbar puncture procedures;
  • Presence of an untreated active infection requiring systemic antiviral therapy at any time during the screening period;
  • Vaccination less than 2 weeks before infusion of vector;
  • Patient who has any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.

Note: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Low dosage group

    2.4x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)

    Genetic: GC101

  • Experimental
    High dosage group

    4.8x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)

    Genetic: GC101

Interventions

  • GeneticGC101

    Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests

    Time frame: when patient reaches 18 months of age

  2. Proportion of patients treated with GC101 who achieve motor milestone of sit unassisted for at least 10 seconds at 18 months of age

    Time frame: when patient reaches 18 months of age

Secondary outcomes

  1. Ability to thrive

    Ability to thrive is defined as the following at 18 months of age: does not receive nutrition through mechanical support or other non-oral method; maintains weight

    Time frame: when patient reaches 18 months of age

  2. Changes from baseline Children's hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score

    CHOP INTEND score ranges from 0 to 64 with higher scores indicating higher motor function

    Time frame: when patient reaches 18 months of age

  3. Proportion of event-free survival patients

    Time frame: when patient reaches 14 months of age

Other outcomes

  1. Proportion of patients who achieve the World Health Organization (WHO) Multicenter Growth Reference Study (MGRS) motor milestones

    WHO MGRS gross motor milestones and performance criteria included sitting without support for at least 10 seconds, Hands-and-knees crawling at least three in a row, standing with assistance for at least 10 seconds, walking with assistance at least five steps, standing alone for at least 10 seconds, and walking alone.

    Time frame: when patient reaches 18 months of age

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
Apr 21, 2023
StartActual
Feb 25, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05824169
Lead sponsor
GeneCradle Inc
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Feb 25, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

GeneCradle, Inc. China
Contact
ind@bj-genecradle.com
86-13501380583

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion